glp 1 and gip Science Behind Glucagon Receptor Agonists for Obesity Research | News & Announcements Mechanisms underlying GLP-1, GIP, and

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality

Remember: Constipation is a common side effect of GLP-1 agonists, but it's manageable with the right strategies

The incretin hormone glucagon-like peptide 1 (GLP-1) has been implicated in the gutrenal axis and incretin-based therapies might reduce the burden of diabetic kidney disease

When oxidative demand approaches the regenerative capacity of nicotinamide adenine dinucleotide (NAD)/ nicotinamide adenine dinucleotide phosphate (NADPH

See how GLP-1s are reshaping diabetes & obesity care.

Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin